Johnson & Johnson announced on November 19, 2026, the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration seeking approval of CAPLYTA (lumateperone) for the treatment of manic or mixed episodes associated with bipolar I disorder in adults.

Key Highlights

  • sNDA submitted: Johnson & Johnson filed with the FDA seeking approval of CAPLYTA for manic or mixed episodes associated with bipolar I disorder in adults.
  • Phase 3 support: The submission is based on two positive pivotal Phase 3 randomized, double-blind, placebo-controlled studies (Study 451 and Study 452) of once-daily CAPLYTA 42 mg versus placebo.
  • Early symptom reduction: According to the filing, CAPLYTA significantly reduced manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3.
  • Primary and key secondary endpoints met: Both studies met the primary endpoint (change from baseline in YMRS total score at Week 3) and key secondary endpoint (change from baseline in CGI-S score at Week 3), according to the filing.
  • Potential fifth indication: If approved, bipolar mania would become the fifth approved use for CAPLYTA in adults, the company disclosed.
  • Current approvals: CAPLYTA is currently approved for bipolar I and II depression (monotherapy and adjunctive), schizophrenia, and MDD as adjunctive therapy; it is not approved for manic or mixed episodes.
  • Disease scope: The filing states an estimated 11 million U.S. adults experience bipolar disorder at some point in their lives.

CAPLYTA sNDA for Bipolar Mania: Study Design and Current Status

Johnson & Johnson (NYSE:JNJ) disclosed the submission of a supplemental New Drug Application to the FDA on November 19, 2026, for CAPLYTA (lumateperone) targeting manic or mixed episodes associated with bipolar I disorder in adults. The company stated the submission follows positive results from Study 451 and Study 452, two pivotal Phase 3 trials in which patients were randomized to receive once-daily lumateperone 42 mg or placebo for three weeks. The primary endpoint in each study was the change from baseline in Young Mania Rating Scale (YMRS) total score at Week 3; the key secondary endpoint was change from baseline in Clinical Global Impression-Severity (CGI-S) score at Week 3.

According to the filing, both studies met their primary and key secondary endpoints, demonstrating "significant and rapid improvement in bipolar mania symptoms and overall illness severity versus placebo." Improvement in manic symptoms was observed as early as Day 3, following two days of treatment. The filing further states that CAPLYTA was well tolerated, with low rates of discontinuation and "a safety profile consistent with prior studies." The company noted that CAPLYTA is currently not approved for the treatment of manic or mixed episodes associated with bipolar I disorder, and FDA review would be required before any such use could be indicated.

John C. Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, R&D, Johnson & Johnson, was quoted in the filing stating: "Our Phase 3 results demonstrate the potential for CAPLYTA to address these needs, and this submission advances our ambition to provide a foundational treatment that can support patients across the evolving course of serious psychiatric disorders." The filing also includes standard Important Safety Information for CAPLYTA, noting risks including increased mortality in elderly patients with dementia-related psychosis, increased risk of suicidal thoughts and actions in people 24 years of age and younger, and other potential serious side effects.

What Was Disclosed

Johnson & Johnson disclosed the filing of an sNDA with the FDA on November 19, 2026, seeking approval of CAPLYTA for bipolar I mania in adults, supported by two positive Phase 3 studies showing significant symptom reduction versus placebo as early as Day 3 through Week 3.